Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CCCC
SELLC4 Therapeutics, Inc. · Healthcare · United States · $376M · Avg Vol: $13M/d
COMPANY DESCRIPTION
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted protein degraders (TPDs) to treat diseases, primarily in oncology and immunology. As a pioneer in the burgeoning field of TPDs, the company leverages its proprietary TORPEDO platform to design highly selective and potent small molecule degraders. C4 Therapeutics is a leading innovator in targeted protein degradation, aiming to revolutionize drug discovery with this novel therapeutic modality.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.1M | 20.8M | 35.6M | 35.9M | 5.0% | 34.9M | 18.9M | 19.1M | -27.0% |
| EPS | -1.16 | -2.67 | -1.52 | -1.27 | — | -1.06 | -0.96 | -1.04 | — |
| Shares | 110.6M | 60.5M | 70.6M | 96.9M | -12.3% | 110.6M | — | — | — |
| Debt | 87.2M | 71.0M | 65.8M | 60.0M | -11.7% | 58.4M | — | — | — |
| Equity | 289.2M | 246.1M | 216.0M | 256.6M | -3.9% | — | — | — | — |
| Op CF | -105.9M | -106.8M | -65.2M | -98.7M | — | -95.4M | — | — | — |
| Inv CF | 58.4M | 158.3M | -51.3M | -8.6M | — | — | — | — | — |
| Fin CF | 1.1M | 45.5M | 45.3M | 126.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CCCC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc.(you) | $376M | 34 | SELL |
| XFOR | X4 Pharmaceuticals, Inc. | $363M | 33 | SELL |
| OVID | Ovid Therapeutics Inc. | $435M | 34 | SELL |
| AVIR | Atea Pharmaceuticals, Inc. | $379M | 29 | SELL |
| TENX | Tenax Therapeutics, Inc. | $385M | 28 | SELL |
| IPSC | Century Therapeutics, Inc. | $381M | 28 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 29 | SELL |
| SGMT | Sagimet Biosciences Inc. | $437M | 30 | SELL |
| OABI | OmniAb, Inc. | $294M | 32 | SELL |
| ELDN | Eledon Pharmaceuticals, Inc. | $276M | 33 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%